GSK unveils 3-year cost-savings plan to fund late-stage R&D, move research HQ to AZ’s backyardfierce biotech
GSK launches cost-saving plan to accelerate drug pipelineWSJ
GSK (GSK) beats second-quarter earnings and revenue estimatesyahoo finance
GSK raises margin outlook, plans $2.5 billion restructuring to fast-track new drugsreuters
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late stage pipeline portfolio. 20+ Phase III trials expected to begin in 2026GSK
